<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parry, Nicola</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Cameron, David A.</style></author><author><style face="normal" font="default" size="100%">Dowsett, Mitchell</style></author><author><style face="normal" font="default" size="100%">Mayer, Ingrid A.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Current Perspectives on Neoadjuvant Treatment of ER-Positive BC</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">19-20</style></pages><abstract><style  face="normal" font="default" size="100%">This article highlights some key aspects about neoadjuvant treatment of endocrine receptor-positive breast cancer, including its use in postmenopausal women, the use of biomarkers for clinical management, and clinical trials investigating the use of novel targeted agents in this setting.</style></abstract><number><style face="normal" font="default" size="100%">56</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>